...has worldwide rights to the once-daily sub-antimicrobial formulation of doxycycline. MediGene had European rights from CollaGenex Pharmaceuticals Inc....
...resistance to the agent. Galderma obtained the delayed-release formulation of doxycycline through its acquisition of CollaGenex Pharmaceuticals Inc....
...Galderma completed its previously announced cash tender offer for shares of CollaGenex at $16.60 per share... ...March 3). Galderma plans to acquire the remaining shares at $16.60 via a merger agreement. CollaGenex Pharmaceuticals Inc....
...has worldwide rights to the once-daily sub-antimicrobial formulation of doxycycline. MediGene had European rights from CollaGenex Pharmaceuticals Inc....
...resistance to the agent. Galderma obtained the delayed-release formulation of doxycycline through its acquisition of CollaGenex Pharmaceuticals Inc....
...Galderma completed its previously announced cash tender offer for shares of CollaGenex at $16.60 per share... ...March 3). Galderma plans to acquire the remaining shares at $16.60 via a merger agreement. CollaGenex Pharmaceuticals Inc....